Oncorus

Recent Finacing

Series B

Recent Raise

$79.5M

Oncorus develops oncolytic virus therapies using a proprietary oncolytic herpes simplex virus platform and a synthetic platform enabling systemic IV delivery, with intratumoral candidate ONCR-177 and engineered safety attenuations.

Founded 2015

Massachusetts, United States

51-100

Publicly Traded

oncorus.com

Highlights

Focus Areas

Biotechnology

Medical

Oncology

Therapeutics

Recent Investors

A

Financials

$84.5M

Total Raised

2

Funding rounds

17

Investors

Team

Upgrade to view the team

See the team members at Oncorus.